01951 JXR
- 3.030
- -0.040-1.30%
JXR News
Starting in June, Chengdu will comprehensively improve medical treatment for maternity
Gelonghui, May 11 | Five departments including the Chengdu Municipal Health Insurance Administration jointly issued the “Notice on Optimizing and Adjusting Maternity Medical Treatment Policies”, which states that starting June 1, the maternity medical benefits for urban workers and urban and rural residents in Chengdu will be comprehensively upgraded. The “Notice” indicates that maternity medical treatment mainly includes prenatal examination fees, maternity medical expenses, etc. The current adjustment in Chengdu has optimized and upgraded the guarantee standards for prenatal examinations and maternity medical expenses. Among them, the fixed subsidy standard for prenatal examinations for insured urban workers was adjusted from 700 yuan to 1,000 yuan; the standard medical expenses for childbirth was 2,000 yuan for miscarriages and difficult births (incl.
Changes in Hong Kong stocks | Jinxin Reproduction (01951) rose more than 10% The National Health and Health Commission will introduce fertility support policies at a press conference in the afternoon
Jinxin Reproduction (01951) rose by more than 10%. As of press release, it rose 9.89% to HK$3, with a turnover of HK$804.516 million.
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
錦欣生殖：2023年報
China Post Securities: Endogenous growth is steady, and the Hong Kong stock healthcare services sector's valuation is highly attractive
Judging from the overall performance of medical service targets in Hong Kong stocks, with the exception of ICL's high revenue base in the early COVID-19 period, where dental revenue was affected by dental implant collection, most of the revenue from other medical service targets increased relatively well.
Changes in Hong Kong stocks | Jinxin Reproduction (01951.HK) rose more than 6% to include assisted reproduction in many places as health insurance companies to expand the assisted reproduction market in Southeast Asia
Jinxin Reproduction (01951.HK) rose more than 6%. As of press release, it rose 6.17% to HK$2.58, with a turnover of HK$29.36,500.
Jinxin Reproduction (1951.HK) 2023 Report Review: The 23-year performance is in line with expectations and is expected to usher in a recovery in 24
Event: The company announced its annual results for '23, achieving annual revenue of 2,789 million yuan, up 18.0% year on year; realized net profit of 347 million yuan, up 194.2% year on year; adjusted net profit of 472 million yuan
Express News | Jinxin Reproduction expands the layout of the assisted reproduction market in Southeast Asia
Jinxin Reproduction (01951.HK) and Indonesia's Morula reached an equity strategic investment cooperation to expand the assisted reproduction market in Southeast Asia
On April 1, 2024, Jinxin Reproductive Medicine Group Co., Ltd. (01951.HK) announced the signing of an equity investment agreement with Indonesia's PT Morula Indonesia (“Morula”). After the investment is completed, Jinxin Fertility will become Morula's largest strategic investor. At the same time, the two sides will reach strategic cooperation, achieve resource integration, and jointly explore the assisted reproduction industry market in Indonesia and Southeast Asia. The population of Southeast Asia is huge and continues to grow. At the same time, with economic development, residents' consumption capacity is also increasing, and the assisted reproduction industry has great potential for growth.
Jinxin Reproduction (01951.HK) Hong Kong Stock Company Information Update Report: Fast recovery in 2023, the new Shenzhen campus is expected to be put into operation in 2025
Performance recovered rapidly in 2023, profitability continued to increase, maintaining the publication of the 2023 annual report by the “buy” rating company. In 2023, the company achieved revenue of 2,789 billion yuan (+18% compared to the same period, the following are all year-on-year ratios).
Open Source Securities: Maintaining Jinxin Reproduction's (01951) “Buy” rating, Shenzhen's new hospital is expected to be put into operation
Open Source Securities estimates that Jinxin Reproduction (01951)'s net profit for 2024-26 will be $3.87/46,538 million yuan.
Jinxin Reproduction (1951.HK): Performance is in line with expectations, domestic and foreign operations have resumed steadily
Incident: The company issued a 2023 results announcement and reviewed that the performance was basically in line with expectations. In 2023, the company achieved revenue of 2,789 billion yuan (+18.0%), the increase was mainly due to 1) the number of domestic patients, special needs services and others after the epidemic
JXR To Go Ex-Dividend On June 27th, 2024 With 0.0595 HKD Dividend Per Share
March 30th - $JXR(01951.HK)$ is trading ex-dividend on June 27th, 2024. Shareholders of record on June 28th, 2024 will receive 0.0595 HKD dividend per share on July 25th, 2024. The ex-dividend dat
Jinxin Reproduction (1951.HK) Annual Report Review: Steady Revenue Growth Continues to Focus on Profit Margin Recovery
Incident: The company announced its 2023 annual report. During the reporting period, it achieved operating income of 2,789 million yuan (+18%); net profit to mother of 345 million yuan (+185%), net profit to mother of 12.4% (+7.2pcts)
Jinxin Reproduction (1951.HK): ARS business is recovering, overseas/new business can be expected
Revenue growth is steady in 2023. I am optimistic that Jinxin Fertility will continue to climb steadily at home and abroad in 2023, achieve revenue of 2.79 billion yuan (+18.0% yoy), and net profit to mother of 345 million yuan (+184.6 million yuan)
Jinxin Reproduction (1951.HK): The number of cycles is growing steadily, and the company's profitability continues to improve
Matters: The company released its 2023 annual report, achieving revenue of 2,789 million yuan (+18.0%); net profit of 347 million yuan (+194.2%); adjusted net profit of 472 million yuan (+72.0%), public
Jinxin Fertility Logs 185% Profit Surge in 2023 as Revenue Rises 18%
Jinxin Fertility Group (HKG:1951) recorded a 184.6% rise in attributable profit for the year ended Dec. 31, 2023, to 344.7 million yuan from 121.1 million yuan in 2022, a filing posted on the Hong Kon
Understand the 2023 annual results highlights of Jinxin Reproduction (01951.HK) in one picture
On March 27, Jinxin Reproduction (01951.HK) announced the results for the year ended December 31, 2023. We will take you to understand the specific results in a chart.
Jinxin Reproduction (1951.HK): Remarkable results after the epidemic, with both high growth and certainty, the right time to invest
In 2023, the birth rate of China's population continued to decline and experienced negative population growth for the first time. Against this backdrop, “Jinxin Reproduction”, the first stock of assisted reproduction, announced financial results for the fiscal year 2023, achieving operating income of 2.79 billion yuan, an increase of 18% over the previous year. Its net profit and adjusted net profit reached 350 million yuan and 470 million respectively, achieving significant increases of 194% and 72% respectively compared to 2022, and even surpassed pre-pandemic levels. At the same time, the company also provided a cash dividend of about HK$164 million, and the dividend payment rate reached 43%.
Intraday quick overview | The three major indices rose sharply, the Keji Index rose more than 2%, Bilibili rose nearly 8%, and JD and Meituan rose more than 5%
Biotech stocks rose, with Yao Ming Biotech up more than 6%, Genting Xinyao by more than 5%, Kingsray Biotech by more than 4%, and BeiGene Shenzhou by nearly 2%; Apple concept stocks generally rose, Ruisheng Technology and Gaowei Electronics by about 5%, and Shunyu Optics and Qiutai Technology by about 2%.
Analysis
Price Target
No Data
